Dosing for your patients who experience sensory neuropathy

Neuropathy (Make a selection)

  • Mild to Moderate
  • Severe
  • Recurrent
MBC dose adjustments for neuropathy

Illustrative purposes only.

Mild to Moderate

  • If neuropathy is mild or moderate (Grade 1 or 2), a dose reduction is generally not needed
MBC dose adjustments for neuropathy

Illustrative purposes only.

Severe

  • If neuropathy is severe (?Grade 3), hold treatment until resolution to Grade 1 or 2, then reduce dose from 260 mg/m2 to 220 mg/m2 for all subsequent courses
Metastatic breast cancer dose adjustments for neuropathy

Illustrative purposes only.

Recurrent

  • If severe (?Grade 3) neuropathy is recurrent, hold treatment until resolution to Grade 1 or 2, then reduce dose from 220 mg/m2 to 180 mg/m2 for all subsequent courses
  • In the phase 3 ABRAXANE MBC clinical trial, sensory neuropathy with any symptoms occurred in 71% of patients receiving ABRAXANE 260 mg/m2 over 30 minutes; sensory neuropathy with severe symptoms (defined as ? Grade 3 toxicity) occurred in 10% of patients receiving ABRAXANE

Dosing for your patients who experience sensory neuropathy

Neuropathy (Make a selection)

  • Mild to Moderate
  • Severe
  • Recurrent
MBC dose adjustments for neuropathy

Mild to Moderate

  • If neuropathy is mild or moderate (Grade 1 or 2), a dose reduction is generally not needed
MBC dose adjustments for neuropathy

Severe

  • If neuropathy is severe (?Grade 3), hold treatment until resolution to Grade 1 or 2, then reduce dose from 260 mg/m2 to 220 mg/m2 for all subsequent courses
Metastatic breast cancer dose adjustments for neuropathy

Recurrent

  • If severe (?Grade 3) neuropathy is recurrent, hold treatment until resolution to Grade 1 or 2, then reduce dose from 220 mg/m2 to 180 mg/m2 for all subsequent courses

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.